Amgen
Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
Jan 31, 2024 · Biogen will focus on LEQEMBI® (lecanemab-irmb) with Eisai and advancing potential new modalities to address the multiple pathologies of the disease and unmet patient needs. A plan for patients participating in clinical trials or on commercially available treatment is in place.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Biogen Announces Webcast of Annual Meeting of Stockholders. June 9, 2024. FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease. June 3, 2024.
Jun 7, 2021 · FDA approves Biogen Alzheimer’s treatment. It is a reflection of “two decades of no innovation” and will also allow the company to further invest in its pipeline of drugs for other diseases ...
